In8bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 31
- Market Cap
- -
- Website
- http://www.in8bio.com
- Introduction
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Phase 1
Active, not recruiting
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- In8bio Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05664243
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Louisville Hospital/James Graham Brown Cancer Center, Louisville, Kentucky, United States